Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
BIKEN to Map Out 5-Year Biz Plan, Eyes Collaboration for PIII: Director
The Research Foundation for Microbial Diseases of Osaka University, better known as BIKEN, is currently drawing up a five-year business plan through FY2019, which will include a numerical sales target in the final year, Director Koichi Yamanishi revealed on July…
To read the full story
Related Article
- BIKEN to Produce and Ship Same Amount of Seasonal Flu Vaccines as Last Season: Director Yamanishi
July 13, 2015
- “4-Company Oligopoly” on Seasonal Flu Vaccines Coming to an End, Era of Mega-Competition Coming to Japan: Dr Yamanishi of BIKEN
May 21, 2015
- BIKEN Begins Clinical Trial of Varicella Vaccine for Herpes Zoster
November 12, 2014
BUSINESS
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
- Lasker Win “Not the Finish Line” for Chugai Researchers; Next-Gen Drug Advances
September 11, 2026
- Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
September 11, 2026
- Silchester Emerges as Suzuken’s Top Shareholder with 10.03% Voting Stake
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…